<?xml version="1.0" encoding="UTF-8"?>
<p id="para1540">According to the GHE 2015 dataset, in mainland China, hepatitis B infection accounted for 63% of all deaths due to cirrhosis and other chronic liver diseases and for 53% of all deaths due to liver cancer, whereas hepatitis C accounted for 6% and 4% of such deaths, respectively (
 <xref rid="tbl2" ref-type="table">table 2</xref> ).
 <xref rid="bib1" ref-type="bibr">
  <sup>1</sup>
 </xref> Acute hepatitis B infection caused 76·7% of acute hepatitis-related deaths in China in 2015; by comparison, hepatitis C caused 3·1%.
 <xref rid="bib1" ref-type="bibr">
  <sup>1</sup>
 </xref> China has the most people infected with HBV and HCV worldwide. In Asia-Pacific, China accounts for a large proportion of the regional burden of viral hepatitis, particularly HBV, with prevalence in 2018 of more than 80 million estimated chronic infections.
 <xref rid="bib4" ref-type="bibr">
  <sup>4</sup>
 </xref> Nevertheless, the country is moving towards elimination of viral hepatitis
 <xref rid="bib4" ref-type="bibr">
  <sup>4</sup>
 </xref> via a universal HBV vaccination programme in infants and mandatory screening of blood products for HBV and HCV,
 <xref rid="bib5" ref-type="bibr">
  <sup>5</sup>
 </xref> and has exceeded WHO's Western Pacific regional target for HBV vaccination and reduction of HBsAg prevalence in children younger than 5 years.
 <xref rid="bib4" ref-type="bibr">
  <sup>4</sup>
 </xref> According to a 2015 systematic review,
 <xref rid="bib6" ref-type="bibr">
  <sup>6</sup>
 </xref> the estimated HBsAg endemicity in mainland China decreased from 14·0% in 1957–89 to 5·4% in 1990–2013. More recently, a modelling study
 <xref rid="bib7" ref-type="bibr">
  <sup>7</sup>
 </xref> estimated HBsAg prevalence in China to be 6·1%. In national surveys, the prevalence of HBsAg in the general population decreased from 9·8% in 1992 to 7·2% in 2006.
 <xref rid="bib8" ref-type="bibr">
  <sup>8</sup>
 </xref> In people aged 1–29 years, the prevalence of HBsAg decreased from 10·1% in 1992 to 5·5% in 2006 and to 2·6% in 2014.
 <xref rid="bib9" ref-type="bibr">
  <sup>9</sup>
 </xref> Nonetheless, there are still an estimated 77–97 million people with chronic HBV infection in China, including more than 20–30 million with active liver disease,
 <xref rid="bib7" ref-type="bibr">
  <sup>7</sup>
 </xref> of whom 7 million need urgent treatment because of advanced fibrosis or high risk of developing hepatocellular carcinoma.
 <xref rid="bib8" ref-type="bibr">
  <sup>8</sup>
 </xref> The average annual cost per case of HBV-related liver disease in China was estimated at US$4454·0 (direct), $924·3 (indirect), and $6611·10 (intangible).
 <xref rid="bib10" ref-type="bibr">
  <sup>10</sup>
 </xref>
</p>
